BioSpace News Archive

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities. As the global COVID-19 pandemic continues to quickly evolve, we have put measures in place intended to safeguard the health of our employees in line with many other companies. In doing so, we aim to do our part to help s

Newly created role will oversee the translation of programs from research stage into the clinic

NanoMosaic L.L.C. announced it is commercializing technology for high-throughput, high-sensitivity analyte detection initially developed at Harvard University, through an exclusive license agreement with Harvard Office of Technology Development.

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, received an official communication from the China National Intellectual Property Administration (“CNIPA”) regarding its intention to grant Chinese Patent Application No. 201380021092.5. Including thi

Rgenta Therapeutics, a new biotechnology company focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets, announced today that it closed a $20 Million seed investment, co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China. Rounding out the series seed syndicate are two

NanoVibronix, Inc ., today announced that it signed a license agreement with Sanuwave Health, Inc. for the manufacture and delivery of its Woudshield technology

Financing to drive development and commercialization of innovative cell & gene therapy processing solution

4G Clinical, a cutting-edge randomization and trial supply management provider, announced the appointment of industry veteran Barry Moore as VP of Delivery.

Axial Biotherapeutics announced positive topline data from its Phase 1b/2a clinical trial of AB-2004, a first-in-class therapeutic that removes certain metabolites from the gastrointestinal tract for the treatment of Autism Spectrum Disorder.

Insmed Incorporated announced the appointment of Carol A. Schafer to its Board of Directors. Ms. Schafer has more than 25 years of experience in investment banking and equity capital markets, and currently serves as a Managing Partner at Hyphen Advisors, LLC.